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httpcense.Abstract Background: Prognostic stratiﬁcation of patients with PE is important in management
and potentially improve clinical outcome. Cardiac biomarkers are used as an adjunct to clinical
and echocardiographic risk stratiﬁcation in a variety of circumstances, (Creatine-kinase-MB
‘‘CK-MB’’) and cardiac troponin I (cTnI) are most widely used because of their high sensitivities,
and very high speciﬁcity of troponin for heart muscle injury. Evidence is mounting that myoglobin’s
sensitivity for myocardial necrosis combined with its unique release and clearance properties may
render it particularly attractive as a risk marker either alone or in combination with other markers.
Objectives: The aim of the current study is to assess the levels of cardiac speciﬁc biomarkers in
relation to different clinical, ECG and echocardiogrphic ﬁndings in patients with acute PE, as well
as evaluating the prognostic value of these biomarkers for inhospital mortality and adverse clinical
events.
Patients and methods: This study comprised 40 patients with proved PE (22 males and 18
females), their mean age was 50.05 ± 13.09 years (range 22–70 years). The following investigations
were performed for all patients; 12-leads ECG, Full echo Doppler study, spiral CT of the chest, and
laboratory testing: arterial blood gas, serum myoglobin, serum troponin, total CK and CK-MB,
kidney and liver function tests.
Result: Signiﬁcant elevation of CK-MB (>10 l/L) was noted only in 7.5% of patients, while
cardiac cTnI was elevated (P0.07 ng/ml) in 45% of patients and elevated serum myoglobin was
found very early after symptoms (<4 h) in 55% of patients. Elevated serum cTnI and myoglobin
were signiﬁcantly associated with ECG signs of right ventricular strain and echocardiographic evi-
dence of right ventricular dysfunction.
Conclusion: The results of the present study demonstrate the prognostic value of cardiac speciﬁc
biomarkers, cardiac troponin I & myoglobin in acute pulmonary embolism. Thus, the current data
combined with the results of previous studies strongly support the integration of troponin and myo-
globin testing into the risk stratiﬁcation and management of patients with established acute PE.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.4195910.
.com (E.O. Arram).
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Acute pulmonary embolism (PE) has a wide spectrum of clin-
ical presentations. The short-term clinical outcome of patients
with PE varies from early recovery of symptoms to hemody-
namic deterioration and death [1]. Echocardiography has
emerged as the principal tool for risk stratiﬁcation in acute
PE. From a prognostic point of view, echocardiography helps
to classify patients with PE, right ventricular dysfunction on
the echocardiogram is an independent and powerful predictor
of early death in patients with acute PE [2].
Among patients with normal blood pressure on admission,
right ventricular (RV) dysfunction at echocardiography (Echo)
identiﬁes those at high risk for in- hospital mortality. In those
patients, elevated levels of cardiac biomarkers have been asso-
ciated with RV dysfunction at Echo [3].
Severe dyspnea, cyanosis, and syncope indicate life-threat-
ening PE. The clinical examination may reveal signs of acute
right ventricular dysfunction, including tachycardia, a low
arterial blood pressure, distended neck veins, an accentuated
P 2, or a tricuspid regurgitation murmur. On the ECG, T-wave
inversion or a pseudoinfarction pattern (Qr) in the anterior
precordial leads indicates right ventricular dilation and dys-
function [4].
Myoglobin is a heme protein found in all striated muscles.
Although the sensitivity of myoglobin for cardiac necrosis is
similar to that of cardiac troponin (Tn) and creatine-kinase
myocardial band (CK-MB), its diagnostic use is limited by
concerns about its lack of speciﬁcity [5]. However, evidence
is mounting that myoglobin sensitivity for myocardial necrosis
combined with its unique release and clearance properties may
render it particularly attractive as a risk marker either alone or
in combination with other markers. Myoglobin may be detect-
able above the upper limits of normal in the serum within
1–3 h of the onset of myocardial injury, but becomes no longer
detectable within 12–18 h. This unique proﬁle offers special
opportunities for using myoglobin in diagnostic and risk
stratiﬁcation purposes [6]. The relationship between serum
levels of myoglobin and clinical outcomes in patients with
PE has been assessed in a limited number of studies, but –
however – remains unclear [2].
Cardiac troponins are the most sensitive and speciﬁc bio-
markers of myocardial cell damage, reﬂecting microscopic
myocardial necrosis [7]. Elevated Tn levels predict adverse out-
comes in patients with acute myocardial infarction (MI) and in
critically ill patients without acute coronary syndromes [8].
Troponin is a regulatory protein of the thin ﬁlament of striated
muscle and consists of 3 subunits: TnC at 18 kDa, cTnI at
21 kDa, and TnT at 37 kDa. The serum levels of TnT and cTnI
are increased for many days after MI, but less elevation occurs
with PE; being of short duration [9].
The current study aimed at assessing the levels of these car-
diac biomarkers in relation to the different clinical, ECG, and
Echo ﬁndings in patients with acute PE; as well as evaluating
the prognostic value of these biomarkers for in-hospital mor-
tality and adverse clinical events in this category of patients.
Patients and methods
This study comprised 40 consecutive patients (22 male and 18
female) aged 50.1 ± 13.1 years. These patients were proved tohave acute PE by spiral contrast-enhanced computed tomogra-
phy (CT) of the chest. Only the patients referred within 12 h of
the onset of symptoms were included in this study.
Exclusion criteria included delayed presentation after the
onset of symptoms, patients with ischemic, valvular, or con-
genital heart diseases, renal or hepatic failure, connective tissue
disorders, endocrine disorders, and recent trauma or surgery.
All patients were subjected to thorough history taking (with
stress on the analysis of chest pain, dyspnea, hemoptysis, and
cardiovascular collapse) and complete general and local exam-
ination. All patients underwent the following investigations:
standard transthoracic 12-leads ECG, full Echo-Doppler study
(to evaluate left ventricular size and function, cardiac valves,
pericardium, RV size and function, pulmonary artery diameter
and pressure), spiral chest CT, and laboratory tests (arterial
blood gases, serum myoglobin, serum troponin, total CK
and CK-MB, kidney and liver function tests).
Clinical end points of the study included overall mortality
and complicated in-hospital course; which is deﬁned as one
or more of the following: need for thrombolytic therapy, cate-
cholamine support of blood pressure, endotracheal intubation
or cardiopulmonary resuscitation. Other in-hospital adverse
clinical events include: ischemic stroke (conﬁrmed by CT
brain) and major bleeding (deﬁned according to standardized
criteria). Recurrent PE was conﬁrmed by spiral chest CT.
The mean duration of in-hospital stay was 25.2 ± 9.6 days.
The cutoff levels of both cTnI and myoglobin in cases of acute
pulmonary embolism (>0.07 ng/ml, >70 ng/ml), respectively,
were applied in the current study as mentioned according to
European guidelines on the diagnosis and management of pul-
monary embolism [10].
Laboratory methods
Venous blood sample (5 ml) was drawn from each patient
through antecubital vein and the separated sera were aliquoted
and preserved at 70 C till the time of Tn, CK-MB, and myo-
globin assay.
cTnI assay: this was estimated using chemiluminscence
autoanalyzer (Imnulite 1000, USA).
Myoglobin assay: this was done through the immunoturbid-
imetry method using automated Cobas Integra instrument
(Roche, Germany).
CK-MB assay: this was done through the immunoinhibi-
tion method.
Statistical methods
Data were analyzed using SPSS program version 16. Qualita-
tive data were presented as number of patients (percentage).
Quantitative data were tested for normality by Kolmogrov–
Smirnov test. Normally distributed data were presented as
mean ± SD. Independent-samples t-test was used to compare
between two groups. Pearson correlation co-efﬁcient was used
to correlate between variables. A two-tailed p-value <0.05 was
regarded as signiﬁcant.
Results
The clinical and other characteristics of the study population
are shown in Table 1. As shown in the table, almost all patients
Table 1 Clinical and other characteristics of the study
population of patients with acute pulmonary embolism on
the time of presentation.
Variables Number
(n= 40)
Percentage (%)
I – Acute symptoms
Dyspnea 38 95
Chest pain 32 80
Hemoptysis 22 55
Lower limb pain
and tenderness
20 50
Syncope 18 45
II – Predisposing factors for
pulmonary embolism
Reduced mobility 24 60
Lowe limb problems 22 55
-Deep vein thrombosis 16 40
-Varicose veins 4 10
-Bone fracture(s) 2 5
Obesity 10 25
Hormonal contraception 2 5
III – ECG changes suggestive of
pulmonary embolism
Recent SI QIII TIII 10 25
Inverted T-wave (V1 through V3) 8 20
Complete/incomplete RBBB 4 10
IV – Echocardiographic evidence
of RV dysfunction
RV enlargement 20 50
Signiﬁcant tricuspid regurge
(P grade III/IV)
18 45
Paradoxical septal motion 16 40
V – Laboratory data
MyoglobinP70 ng/ml 22 55
Troponin-IP0.07 ng/ml 18 45
CK-MBP10 U/L 3 7.5
CK-MB, creatine-kinase myocardial band; ECG, electrocardio-
graphic; RBBB, right bundle branch block; RV, right ventricular.
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(80%); while 60% of the patients had reduced mobility as
the commonest predisposing factor for acute PE. The com-
monest ECG change which existed in these patients was recent
SI QIII TIII (25%); while the commonest Echo ﬁnding was RV
enlargement (half the cases).
Elevated levels of cardiac tissue-speciﬁc biomarkers were
detected in high percentage of patients: elevated (P70 ng/ml)
serum myoglobin levels existed in 55% of patients; while ele-
vated serum cTnI levels (P0.07 ng/ml) existed in 45% of them.Table 2 Correlation between the values of different clinical variabl
Myoglobin (ng/ml)
R
Respiratory rate (cycle/minute) 0.528
Systolic blood pressure (mmHg) 0.647
Diastolic blood pressure (mmHg) 0.659
Mean blood pressure (mmHg) 0.660
** p< 0.01.However, elevated serum CK-MB levels (P10 U/L) existed
only in 7.5% of patients with acute PE. The cut-off values used
in this study to deﬁne elevated levels of cardiac tissue-speciﬁc
biomarkers are derived from the European Guidelines [10].
Signiﬁcant and strong positive correlations existed between
myoglobin serum levels and respiratory rate; while the same
variable correlated negatively and strongly with the values of
systolic, diastolic, and mean arterial blood pressure. cTnI lev-
els correlated positively with respiratory rate, but showed no
signiﬁcant correlation with the values of systolic, diastolic, or
mean arterial blood pressure as shown in Table 2.
As shown in Table 3, signiﬁcantly higher mean values of all
cardiac biomarkers existed in relation to the presence of ECG
signs of RV strain; namely recent SI QIII TIII, right bundle
branch block, and inverted T-waves (in V1 through V3).
As shown in Table 4, statistically signiﬁcant positive corre-
lations existed between RV diastolic diameter (indicator of RV
enlargement) and the levels of all cardiac biomarkers; but this
correlation was particularly strong in the case of myoglobin
followed by cTnI then CK-MB. Signiﬁcant tricuspid regurge
correlated positively and strongly with cTnI levels; and moder-
ately with CK-MB then myoglobin levels in this order of
strength. The values of fractional shortening and pulmonary
artery pressure correlated negatively with CK-MB levels; but
had no signiﬁcant correlation with myoglobin or cTnI levels.
Table 5 and Fig. 1 show the incidence of in-hospital adverse
clinical events in the studied population. As shown in the table,
the commonest event was the administration of thrombolytic
therapy (44% of patients) followed by hemodynamic support
by catecholamine (10% of patients); while the least common
events were recurrent PE and death (5% for each).
Multiple step-wise logistic regression analysis model was
constructed to extract the variables independently associated
with in-hospital mortality and adverse clinical events. As
shown in Table 6, elevated levels of cTnI and myoglobin were
signiﬁcantly and independently associated with very high odds
(14–17 times) of in-hospital mortality and adverse clinical
events.
Discussion
The rapid evaluation and risk stratiﬁcation of patients present-
ing with symptoms suggestive of acute PE are of great clinical
relevance. Biomarkers have become increasingly important in
this setting, especially cardiac troponin, which is still the main
routinely used marker due to its myocardial tissue-speciﬁcity
and sensitivity. Although myoglobin serum level increases
after myocardial injury (even before detectable rise of cardiac
troponin levels), myoglobin was not adequately evaluated in
acute PE [11]. Considering the latter fact, this study wases and the levels of serum myoglobin and troponin-I.
Troponin-I (ng/ml)
p R p
<0.001** 0.410 <0.001**
<0.001** 0.142 0.383
<0.001** 0.053 0.744
<0.001** 0.089 0.584
Table 4 Correlations between the levels of cardiac biomarkers and the values of different Echo variables in patients with acute
pulmonary embolism.
Variable Myoglobin (ng/ml) Troponin-I (ng/ml) CK-MB (U/L)
R p R p R p
RVEDD (cm) 0.534 <0.001** 0.475 0.002** 0.376 0.017*
LVESD (cm) 0.051 0.754 0.190 0.241 0.193 0.232
LVEDD (cm) 0.063 0.698 0.121 0.458 0.091 0.576
LAD (cm) 0.141 0.384 0.112 0.490 0.063 0.698
EF (%) 0.255 0.112 0.215 0.182 0.283 0.077
FS (%) 0.301 0.059 0.255 0.112 0.352 0.026*
PAP (mmHg) 0.035 0.830 0.055 0.734 0.320 0.044*
TR# 0.349 0.027* 0.545 <0.001** 0.379 0.016*
CK-MB, creatine-kinase myocardial band; EF, ejection fraction; FS, fractional shortening; LAD, left atrial diameter; LVEDD, left ventricular
end-diastolic diameter; LVESD, left ventricular end-systolic diameter; PAP, pulmonary artery pressure; RVEDD, right ventricular end-diastolic
diameter; TR, signiﬁcant tricuspid regurge (Pgrade III/IV).
* p< 0.05.
** p< 0.01.
# Spearman rank correlation.
Table 5 Incidence of in-hospital adverse clinical events in studied group of patients with acute pulmonary embolism.
Events Number (n= 40) Percentage (%)
Thrombolytic therapy 22 55
Hemodynamic support by catecholamine 4 10
Cardiopulmonary resuscitation 3 7.5
Recurrent pulmonary embolism 2 5
Death 2 5
Table 3 Comparison of mean values of cardiac biomarkers in patients with acute pulmonary embolism with and without suggestive
ECG ﬁndings.
Variables Recent SI QIII TIII Complete/incomplete RBBB Inverted T (V1 through V3)
+ve (n = 10) ve (n = 30) p +ve (n = 4) ve (n = 36) p +ve (n = 8) ve (n = 32) p
Myoglobin (ng/ml) 87.0 ± 8.8 65.0 ± 7.5 <0.001** 91.0 ± 8.67 81 ± 6.67 <0.001** 84 ± 7.98 79 ± 6.12 <0.001**
Troponin-I (ng/ml) 0.089 ± 0.0092 0.062 ± 0.0057 <0.001** 0.096 ± 0.011 0.081 ± 0.0091 0.004** 0.11 ± 0.0085 0.095 ± 0.0076 <0.001**
CK-MB (U/L) 24.5 ± 3.5 17.4 ± 2.2 <0.001** 28.9 ± 4.4 19.8 ± 3.1 <0.001** 34.5 ± 2.8 19.1 ± 2.6 <0.001**
CK-MB, creatine-kinase myocardial band; RBBB, right bundle branch block.
** p< 0.01.
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myoglobin and other tissue-speciﬁc cardiac biomarkers (cTnI
and CK-MB) in patients with acute PE.
Cardiac troponins are widely established in clinical prac-
tice, but their detection in the circulation may require several
hours after the onset of symptoms. Therefore, the troponin
levels measured on admission may not sufﬁce to assess the
prognosis and guide early therapeutic decisions, pointing to
the need for novel biomarkers and algorithms that guarantee
more efﬁcient and (particularly) faster risk assessment of acute
PE [12,13].
Our results demonstrate that nearly half (45%) the patients
diagnosed with PE have elevated cTnI level, so that testing this
biomarker could help to identify patients with RV dysfunction
who had higher risk of adverse clinical outcome. Thus, cTnI
assay is useful to detect minor myocardial damage in PEpatients as previously conﬁrmed by Meyer et al. [14]. Elevated
cTnI serum levels were also correlated with ECG and Echo cri-
teria of RV dysfunction, indicating irreversible myocardial cell
damage. In this respect, it is known that the release of cTnI is
related to acute RV shear stress, with ensuing microinjury and
microinfarctions [15]. Besides, a dilated overloaded RV in-
creases oxygen demand and diminishes perfusion of the right
coronary artery, even in the absence of atherosclerosis [16].
The observed cTnI release in patients with acute PE in this
study is quantitatively small far less than typically observed
in an ST-elevation MI [15,17]. However, cTnI level correlated
well with RV dysfunction in this study, a result conﬁrmed in a
previous report [15].
Elevated cTnI serum levels were independently associated
with mortality and adverse in-hospital clinical events. Both pa-
tients who died during hospitalization had elevated cTnI level
Figure 1 The incidence of in-hospital clinical events in patients with acute pulmonary embolism.
Table 6 The ﬁnal results of the multiple step-wise logistic regression analysis model used to extract the variables independently
associated with in-hospital mortality and adverse clinical events. As shown, elevated levels of troponin-I and myoglobin were
signiﬁcantly and independently associated with very high odds (14–17 times) of in-hospital mortality and adverse clinical events.
Variables Overall in-hospital mortality (odds ratio) In-hospital adverse clinical events (odds ratio)
Troponin-I (ng/ml)
<0.07 ng/ml 6.1 [0.6–62.0] p= 0.085 2.2 [0.8–10.3] p= 0.069
>0.07 ng/ml 15.8 [1.5–166.7] p= 0.018* 14.4 [2.8–51.6] p< 0.001**
Myoglobin (ng/ml)
<70 ng/ml 5.1 [0.6–59.0] p= 0.076 2.1 [0.7–4.2] p= 0.059
>70 ng/ml 16.7 [1.6–165.6] p= 0.002* 17.2 [2.6–49.6] p< 0.001**
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elevated myoglobin levels >70 ng/ml, as well as echocardio-
graphic evidence of RV dysfunction; and all these ﬁndings
are supported by other investigators [9,18].
Elevated serum levels of myoglobin occurred very early
after the onset of symptoms (<4 h) in 55% of patients, and
were strongly associated with ECG and Echo ﬁndings sugges-
tive of RV dysfunction, in line with the previous ﬁnding of Bo-
chowicz et al. [19].
We found a strong positive correlation between elevated
serum myoglobin levels and respiratory distress (indicated by
tachypnea), while there was a strong negative correlation
between serum myoglobin levels and hemodynamic status
(indicated by systolic, diastolic, and mean arterial blood pres-
sure). These ﬁndings could be translated as follows: the
patients with more respiratory distress and/or hemodynamic
instability may have higher serum levels of myoglobin, which
in turn reﬂect more RV dysfunction, a ﬁnding that favors early
thrombolytic therapy. These results are similar to the report of
Pruszczyk et al. [20]. Myoglobin sensitivity for myocardial
necrosis combined with its unique release and clearance prop-
erties may render it particularly attractive as a risk marker,
either alone or in combination with other markers [6,11].The observed myoglobin release is quantitatively small far
less than typically observed in MI (>239 ng/ml) [21]. However,
mildly elevated myoglobin (>70 ng/ml) in acute PE correlated
well with RV dysfunction by Echo and was independently asso-
ciated with very high odds of in-hospital mortality and adverse
clinical events using multivariately-adjusted logistic regression
analysis model. These ﬁndings are almost similar to those re-
ported by Pruszczyk et al. [20] who found elevated myoglobin
levels in almost half the patients with acute PE on admission.
Thus, myoglobin – this instantly elevated marker – is a very use-
ful tool for early risk stratiﬁcation of patients with acute PE,
facilitating the choice of an appropriate therapeutic strategy
that could in turn positively affect the patient’s prognosis.
As in the case of myoglobin, the risk for in-hospital adverse
clinical events and mortality was signiﬁcantly higher in pa-
tients with high cTnI but not CK-MB levels using the same
multivariate logistic regression analysis. Thus, CK-MB was
not found to be an independent predictor of a complicated
in-hospital course in this study; because it was elevated in just
3 patients (7.5%). These results are in accordance with the re-
ports of other studies [15,16,19].
Although the results obtained with both troponin and
myogloblin were directionally similar, the major superiority
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stant release dynamics of myoglobin (within 4 h of the onset of
PE) that may favorably affect risk stratiﬁcation of patients and
hence planning the suitable therapeutic strategy. In other
words, it can be proposed that cardiac troponin and
myoglobin levels should be obtained in normotensive patients
with acute PE to assist clinicians in management. Those
patients with normal troponin and myoglobin can almost
certainly be treated with anticoagulation therapy alone. If con-
cern persists about the prognosis in individual patients, the
prediction of benign clinical course can be conﬁrmed with
Echo, showing normal or near normal RV function. On the
other hand, patients with acute PE and elevated troponin
and myoglobin levels should undergo further testing of RV
function with Echo. If the echocardiogram shows moderate
or severe RV dysfunction in the presence of elevated troponin
and myoglobin levels, this may portend a lethal combination.
This last category of patients should be emergently assessed to
determine whether thrombolysis or embolectomy is the appro-
priate strategy in this setting.
Conclusion
The results of this study strongly support the integration of
troponin and myoglobin testing in management algorithms
of patients with established acute PE, particularly myoglobin,
owing to on its unique instant release in acute PE which makes
it a valuable cardiac biomarker for early planning of instant
therapeutic strategies. Additional therapeutic trials are needed
to determine whether troponin and myoglobin (alone or in
combination with clinical and/or Echo ﬁndings) suggestive of
RV dysfunction can be used to guide the treatment of patients
with acute PE and particularly improve the prognosis of high-
risk patients.
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